These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7758056)

  • 41. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain].
    Rejas Gutiérrez J; Blanca Tamayo M; Gascón Barrachina J; Armada Peláez B
    Rev Psiquiatr Salud Ment; 2016; 9(2):87-96. PubMed ID: 26475204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations.
    Beer K
    J Drugs Dermatol; 2010 Jan; 9(1):27-30. PubMed ID: 20120422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Clinicoecon Outcomes Res; 2013; 5():611-21. PubMed ID: 24348057
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does direct-to-consumer advertising of antidepressants lead to a net social benefit?
    Jureidini J; Mintzes B; Raven M
    Pharmacoeconomics; 2008; 26(7):557-66; discussion 567-8. PubMed ID: 18563947
    [No Abstract]   [Full Text] [Related]  

  • 47. Cost of treatment failure for major depression: direct costs of continued treatment.
    Baker CB; Woods SW
    Adm Policy Ment Health; 2001 Mar; 28(4):263-77. PubMed ID: 11577654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Debits and credits in the management of depression.
    Henry JA
    Br J Psychiatry Suppl; 1993 Jul; (20):33-9. PubMed ID: 8352915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antidepressant selection and economic outcome: a review of methods and studies from clinical practice.
    Crown WH
    Br J Psychiatry Suppl; 2001 Sep; 42():S18-22. PubMed ID: 11532822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Influenza virus genome structure and encoded proteins].
    Nakajima K
    Nihon Rinsho; 1997 Oct; 55(10):2542-6. PubMed ID: 9360369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Taxol (paclitaxel): mechanisms of action.
    Horwitz SB
    Ann Oncol; 1994; 5 Suppl 6():S3-6. PubMed ID: 7865431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications.
    Revicki DA; Wood M
    J Affect Disord; 1998 Feb; 48(1):25-36. PubMed ID: 9495599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nitric oxide and septic shock.
    Thiemermann C
    Gen Pharmacol; 1997 Aug; 29(2):159-66. PubMed ID: 9251894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prospective, 24-week assessment of cost-efficacy of and compliance to antidepressant medications in a rural setting (PACECAR) study.
    Rao TSS; Manohar JS; Raman R; Darshan MS; Tandon A; Karthik KN; Saraswathi N; Das K; Harsha GT; Kunkeri SP; Andrade C
    Indian J Psychiatry; 2017; 59(2):157-163. PubMed ID: 28827861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacoeconomic evaluation of antidepressants : a critical appraisal of methods.
    Iqbal SU; Prashker M
    Pharmacoeconomics; 2005; 23(6):595-606. PubMed ID: 15960555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic considerations in the prescribing of third-generation antidepressants.
    Montgomery S; Doyle JJ; Stern L; McBurney CR
    Pharmacoeconomics; 2005; 23(5):477-91. PubMed ID: 15896099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The economics of selective serotonin reuptake inhibitors in depression: a critical review.
    Frank L; Revicki DA; Sorensen SV; Shih YC
    CNS Drugs; 2001 Jan; 15(1):59-83. PubMed ID: 11465013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The need for an iterative process for assessing economic outcomes associated with SSRIs.
    Skaer TL; Sclar DA; Robison LM; Galin RS
    Pharmacoeconomics; 2000 Sep; 18(3):205-14. PubMed ID: 11147388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A critical review of published economic modelling studies in depression.
    Jones MT; Cockrum PC
    Pharmacoeconomics; 2000 Jun; 17(6):555-83. PubMed ID: 10977394
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sertraline. A pharmacoeconomic evaluation of its use in depression.
    Davis R; Wilde MI
    Pharmacoeconomics; 1996 Oct; 10(4):409-31. PubMed ID: 10184609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.